Get the Stockscreener App
0.561
1.23%
-0.007
Pre-market:
.57
0.009
+1.60%
Oncolytics Biotech Inc stock is traded at $0.561, with a volume of 214.46K.
It is down -1.23% in the last 24 hours and down -10.31% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.568
Open:
$0.5588
24h Volume:
214.46K
Relative Volume:
0.21
Market Cap:
$51.09M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-2.121
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
+12.18%
1M Performance:
-10.31%
6M Performance:
-56.17%
1Y Performance:
-46.06%
1-Day Range:
$0.5466
$0.568
1-Week Range:
$0.5002
$0.65
52-Week Range:
$0.4679
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.561 | 51.09M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Small-cap cancer therapy innovator raises $20M in flexible funding - MSN
Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) - Aktiellt
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
Buzz on the Bullboards: Energy, cannabis, and biotech shine on the TSX | 2025-04-17 | Investing News - Stockhouse
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech : reg; Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer - marketscreener.com
Oncolytic Virus Therapy Market Size, Share and Strategic - openPR.com
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - The Malaysian Reserve
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers - Eastern Progress
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Developm - GuruFocus
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Inc - Baystreet.ca
Small-cap cancer therapy innovator raises $20M in flexible funding | 2025-04-11 | Investing News - Stockhouse
Oncolytics secures $20 million to advance cancer therapy development - The Pharma Letter
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. - GuruFocus
Oncolytics Biotech Secures $20 Million Funding for Pelareorep Development - TipRanks
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital - Barchart.com
Oncolytics Biotech® Inc. - MENAFN.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Stocks In Play: Oncolytics Biotech® Inc. - Barchart.com
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech’s Pelareorep Gains Attention at Key Oncology Event - TipRanks
Cancer Experts Reveal Promising Outlook for Revolutionary Immunotherapy Treatment - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
(ONC) Optimized Trading Opportunities (ONC:CA) - news.stocktradersdaily.com
What Nvidia Stock Investors Should Know About Recent Tariff Updates - The Globe and Mail
Mideast stock markets tumble as US tariffs and low oil prices squeeze energy-producing nations - The Globe and Mail
Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer - ACCESS Newswire
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies - Quantisnow
Virtu Financial LLC Invests $90,000 in Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing - MSN
What is Leede Financial’s Estimate for ONCY FY2025 Earnings? - The AM Reporter
FY2027 EPS Estimate for Oncolytics Biotech Lifted by Analyst - Defense World
TSE:ONC FY2025 EPS Estimate Lifted by Leede Financial - Defense World
HC Wainwright Has Bearish Forecast for ONCY FY2029 Earnings - Defense World
HC Wainwright Cuts Earnings Estimates for Oncolytics Biotech - Defense World
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference - GuruFocus.com
Biotech Advancing Pivotal Phase III Breast Cancer Trial - Streetwise Reports
Bridgewater Systems and Oncolytics Biotech Inc. Under Current Evaluation - ACCESS Newswire
Oncolytics Biotech (NASDAQ:ONCY) Given Buy Rating at HC Wainwright - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $3.00 by Analysts at Maxim Group - Defense World
Oncolytics Biotech: Continuing To Justify The Negativity - Seeking Alpha
Oncolytics Biotech’s Promising Advancements and Strategic Developments Drive Buy Rating - TipRanks
Oncolytics price target lowered to $3 from $5 at Maxim - TipRanks
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - PR Newswire
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):